VarmX raises € 12.5 million to develop VMX-C001
Funding enables clinical stage trials of lead compound VMX-C001.
Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors
VarmX announces publication in Nature Communications of groundbreaking snake venom inspired approach to restore blood clotting in patients using anticoagulants.
VarmX raises seed capital for development of VMX-C001
Restoring blood clotting in patients using anticoagulants.